Financial health
- Operating income covered interest expense -97.8× in the latest year.
Shareholder returns
- Dividends have been paid for 1 consecutive year.
GTBP Financials GT Biopharma, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$28M | — | — | -490.0% | -349.8% | — | — | $7M |
| 2024 | — | -$13M | — | — | 788.1% | -311.0% | — | — | $4M |
| 2023 | — | -$8M | — | — | -101.6% | -53.8% | — | — | $1M |
| 2022 | — | -$21M | — | — | -178.0% | -124.8% | — | — | $6M |
| 2021 | — | -$58M | — | — | -264.8% | -180.3% | — | — | $9M |
| 2020 | $0 | -$28M | — | — | 96.1% | -499.8% | — | — | $5M |
| 2019 | $0 | -$39M | — | — | 200.1% | -9759.3% | -$4M | — | $28000 |
| 2018 | — | -$259M | — | — | -2279.6% | -1020.5% | -$11M | — | $60000 |
| 2017 | — | -$144M | — | — | -57.3% | -56.7% | -$5M | — | $576000 |
| 2016 | — | $10M | — | — | -51.6% | 39072.0% | -$2M | — | $19000 |
| 2015 | — | -$21M | — | — | 42.4% | -39742.6% | -$5M | — | $47000 |
| 2014 | — | -$23M | — | — | 79.4% | -2645.2% | -$2M | — | $855000 |
| 2013 | — | -$501000 | — | — | 7.9% | -340.8% | -$442000 | — | $43000 |
| 2012 | — | -$5M | — | — | 81.6% | -2288.1% | -$989000 | — | $123000 |
| 2011 | — | -$4M | — | — | 72.5% | -2868.2% | -$963000 | — | $92000 |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$5M | — | — | -126.6% | — | — | — | $5M |
| Mar '26 | — | -$3M | — | — | -37.4% | — | — | — | $9M |
| Dec '25 | — | -$23M | — | — | -398.0% | -284.1% | — | — | $7M |
| Sep '25 | — | $8M | — | — | 276.6% | 192.1% | — | — | $3M |
| Jun '25 | — | -$30M | — | — | 116.6% | -423.5% | — | — | $5M |
| Mar '25 | — | -$776000 | — | — | 79.2% | — | — | — | $2M |
| Dec '24 | — | -$4M | — | — | 226.0% | -89.2% | — | — | $4M |
| Sep '24 | — | -$3M | — | — | -162.7% | -50.5% | — | — | $6M |
| Jun '24 | — | -$4M | — | — | -67.4% | -40.0% | — | — | $9M |
| Mar '24 | — | -$2M | — | — | -42.7% | -22.9% | — | — | $2M |
| Dec '23 | — | -$3M | — | — | -39.6% | -21.0% | — | — | $1M |
| Sep '23 | — | -$2M | — | — | -24.1% | -15.0% | — | — | $3M |
| Jun '23 | — | -$2M | — | — | -16.9% | -11.0% | — | — | $3M |
| Mar '23 | — | -$227000 | — | — | -1.7% | -1.1% | — | — | $2M |
| Dec '22 | — | -$6M | — | — | -47.6% | -33.4% | — | — | $6M |
| Sep '22 | — | -$7M | — | — | -43.1% | -32.7% | — | — | — |
| Jun '22 | — | -$3M | — | — | -19.3% | -12.3% | — | — | — |
| Mar '22 | — | -$5M | — | — | -30.6% | -19.8% | — | — | — |
| Dec '21 | — | -$18M | — | — | -82.3% | -56.0% | — | — | $9M |
| Sep '21 | $0 | -$5M | — | — | -17.1% | — | — | — | — |
Frequently asked questions
Is GTBP growing its revenue and profit?
See the revenue and net-income charts above for GT Biopharma, Inc.'s multi-year trend.
How much debt does GTBP have?
As of FY2025, GT Biopharma, Inc. reported — of total debt against $7M of cash; operating income covered interest expense -97.8×.
What is GTBP's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.